近期，北京北陆药业股份有限公司（以下简称"公司"）通过了巴西国家 卫生监督局（以下简称"巴西 ANVISA"）的 GMP（药品生产质量管理规范） 认证，具体情况如下： 一、认证信息 证书类型：CBPF 股票代码：300016 股票简称：北陆药业 公告编号：2024-064 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于公司通过巴西国家卫生监督局GMP认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 认证公司：北京北陆药业股份有限公司 公司地址：北京市密云区水源西路 3 号 认证编号：1257307-FILE(s): 0734701/23-3 由于医药行业的特点，相关产品在国际市场的销售情况易受到市场环境变 化、汇率波动等因素影响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 北京北陆药业股份有限公司 董事会 二○二四年十月三十一日 2 认证范围：大容量注射液，小容量注射液（最终灭菌） 决议日期：2024 年 10 月 3 日 二、对公司的影响及风险提示 巴西是南美洲最大的国家，公司本次顺利通过巴西 ANVIS ...

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 10 月 31 日投资者关系活动记录表 编号：【2024】第 029 号 | --- | --- | --- | |-----------------------|-----------------------------------------------------|----------------------------------------------------------| | 投资者关系 \n活动类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | | 平安医药：臧文清 | 平安医药：韩盟盟 | | | 平安医药：叶寅 | 开源证券：阮帅 | | | 上海雪石资管：吴曦 | 中海基金：姚晨曦 | | | 深圳翼虎投资：熊斌 | 浙江英睿资管：王俊杰 | | 参与单位名称 | 颢升私募基金：夏敬慧 | 中信建投基金：杨经华 | | 及人员姓名 | 金百镕投资：马学进 | 中邮证券：鲁春娥 | ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥255,786,983.47, representing a year-on-year increase of 20.77%[2] - The net profit attributable to shareholders for the same period was ¥4,853,098.55, a significant increase of 163.36% compared to the previous year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,104,651.19, up 145.62% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0099, an increase of 163.46% year-on-year[3] - The diluted earnings per share for the same period was ¥0.0292, showing a remarkable increase of 906.90% compared to the previous year[3] - Total operating revenue for Q3 2024 reached ¥729,717,058.01, an increase of 12.3% compared to ¥649,819,616.22 in the same period last year[21] - Net profit for Q3 2024 was ¥19,003,632.36, a significant recovery from a net loss of ¥4,214,435.41 in the previous year[22] - Earnings per share (EPS) for Q3 2024 were reported at ¥0.0497, compared to ¥0.0040 in the same quarter last year, indicating a substantial improvement[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥137,565,034.78, reflecting a 124.68% increase compared to the same period last year[7] - Operating cash inflow for the period reached ¥864,976,237.96, an increase of 26.4% compared to ¥684,165,993.62 in the previous period[23] - Net cash flow from operating activities was ¥137,565,034.78, significantly up from ¥61,225,996.09 in the prior period, marking a 125.0% increase[23] - Cash inflow from financing activities was ¥148,374,600.00, down from ¥295,519,043.58 in the previous period, reflecting a decrease of 49.9%[24] - Net cash flow from financing activities was ¥635,488.11, a decline from ¥46,618,494.57 in the prior period[24] - The ending balance of cash and cash equivalents was ¥244,766,266.16, a significant decrease from ¥736,672,781.82 in the previous period[24] - The company received ¥20,339,652.89 in other operating cash related to business activities, up from ¥15,246,185.69 in the previous period, representing a 33.6% increase[23] - The company reported a cash inflow of ¥832,994,246.29 from other investment activities, a substantial increase from ¥430,300,000.00 in the previous period[24] - The company’s cash flow from sales of goods and services was ¥839,138,771.77, compared to ¥663,150,517.07 in the previous period, reflecting a growth of 26.6%[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,010,674,509.18, a 6.78% increase from the end of the previous year[3] - The total assets increased to 3,010,674,509.18 yuan, up from 2,819,424,047.96 yuan in the previous period, reflecting a growth in the company's asset base[17] - The company’s non-current assets totaled 1,797,059,111.75 yuan, an increase from 1,622,631,959.82 yuan, indicating growth in long-term investments[17] - The total liabilities increased to ¥1,162,669,414.13 from ¥1,033,111,812.55, representing a growth of 12.5% year-over-year[21] - The company’s total liabilities increased, with accounts payable rising to 100,258,362.68 yuan from 95,057,517.19 yuan, reflecting higher operational costs[17] - The company's short-term borrowings increased to 190,304,423.34 yuan from 175,563,188.54 yuan, indicating a rise in debt levels[17] Research and Development - The company has made progress in its R&D projects, although some projects have not yet reached milestone nodes, leading to a temporary reduction in R&D expenditures[7] - Research and development expenses for the quarter were ¥53,171,942.94, a decrease of 38.4% from ¥86,346,507.94 in the previous year[21] Product Development and Market Operations - The company is actively promoting products included in centralized procurement and has seen steady growth in overseas market operations, contributing to revenue growth[7] - The company received approvals for several products, including Gadobutrol injection and Paroxetine hydrochloride enteric-coated sustained-release tablets, enhancing its product portfolio[14] Inventory and Receivables - Inventory rose to 323,934,232.06 yuan, compared to 244,859,077.90 yuan previously, suggesting an increase in stock levels[16] - Accounts receivable decreased to 154,380,207.23 yuan from 185,043,282.81 yuan, showing improved collection efficiency[16] - The company reported a total of 1,213,615,397.43 yuan in current assets, slightly up from 1,196,792,088.14 yuan[16]

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-061 北京北陆药业股份有限公司 关于钆喷酸葡胺注射液通过一致性评价的公告 1 上市许可持有人：北京北陆药业股份有限公司 上市许可持有人地址：北京市密云区水源西路 3 号 生产企业：北京北陆药业股份有限公司 生产企业地址：北京市密云区水源西路 3 号 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。有效期为 18 个月。药品上市许可持有人应当在批准之日起 6 个月内实施变更。 2、钆喷酸葡胺注射液 12ml：5.63g（按 C₁₄H₂₀GdN₃O₁₀·2C₇H₁₇NO₅计） 英文名/拉丁名：Gadopentetate Dimeglumine Injection 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的规格分别为 10ml：4.69g、12ml：5.63g 的钆喷酸葡胺注射 液《药品补充申请批准通知书》（通知书编号：2024B04775、2024B04774） ...

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-060 北京北陆药业股份有限公司 关于控股子公司海昌药业通过药品GMP符合性检查的公告 二、对公司影响及风险提示 2024 年 10 月 9 日，浙江省药品监督管理局发布《浙江省药品监督管理局 第 0188 号 GMP 符合性检查结果》。北京北陆药业股份有限公司（以下简称"公 司"）控股子公司浙江海昌药业股份有限公司（以下简称"海昌药业"）原料药 （碘克沙醇）合成三车间、合成四车间、精烘包车间，生产线 2 通过 GMP 符 合性检查，具体情况如下： 一、 GMP 符合性检查相关信息 企业名称：浙江海昌药业股份有限公司 地址：浙江省玉环市沙门镇滨港工业城长顺路 36 号 检查范围：原料药（碘克沙醇） 生产车间生产线：合成三车间、合成四车间、精烘包车间，生产线 2 检查时间：2023 年 10 月 24 日至 2023 年 10 月 27 日 检查结果：结果符合要求 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次海昌药业碘克沙醇原料药通过药品GMP 现 ...

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-058 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300016 证券简称：北陆药业 北京北陆药业股份有限公司 关于 2024 年第三季度可转换公司债券转股情况的公告 债券代码：123082 债券简称：北陆转债 转股价格：人民币8.68元/股 转股时间：2021 年 6 月 11 日至 2026 年 12 月 6 日 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，北京北陆药业股份 有限公司（以下简称"公司"）现将 2024 年第三季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动的情况公告如下： 一、可转债发行上市概况 （一）可转债发行上市基本情况 经中国证券监督管理委员会证监许可〔2020〕2810号文同意注册，公司 于2020年12月7日向不特定对象发行500万张可转换公司债券，每张面值100 元，发行总额50,000.00万元。 （二）可 ...

股票代码：300016 股票简称：北陆药业 公告编号：2024-059 债券代码：123082 债券简称：北陆转债 关于硫酸钠化学原料药获批上市的公告 英文名/拉丁名：Sodium Sulfate 化学原料药注册标准编号：YBY72242024 有效期：24 个月 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的硫酸钠化学原料药上市申请批准通知书。现将相关情况公 告如下： 北京北陆药业股份有限公司 一、药品的基本情况 化学原料药通用名称：硫酸钠 通知书编号：2024YS01013 包装规格：25kg/桶 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。 生产企业名称：北京北陆药业股份有限公司 1 生产企业地址：河北省沧州市临港经济技术开发区西区北京医药产业园经 六路纬二路 登记号：Y20230000271 受理号：CYHS2360306 通知书有效期：至 2029 年 9 月 29 日 ...

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 9 月 20 日投资者关系活动记录表 编号：【2024】第 027 号 | --- | --- | --- | |-------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称 及人员姓名 | 太平洋证券：周豫、刘哲涵 | | | 时 间 | 2024 年 9 月 20 日 | | | 地 点 | 公司会议室 | | | 上市公司接 待人员姓名 | 证券事务代表：孙志芳 | | | | ...

Group 1: Financial Performance - In the first half of 2024, the company achieved sales revenue of 279.81 million yuan, representing a year-on-year growth of 10.85% [2] - The company has gradually overcome challenges posed by price reductions in its main contrast agent products, showing signs of recovery [2] Group 2: Product Development and Market Expansion - The company has successfully expanded its gadolinium-based contrast agent product line, now including four products, enhancing its market competitiveness [2] - The marketing and sales efforts for gadobenate dimeglumine injection have officially commenced, expected to further drive revenue growth [2] Group 3: Production Base and Strategic Planning - The company strategically selected Bozhou, Anhui Province, for its production base, aiming to strengthen its position in the traditional Chinese medicine sector [3] - The Bozhou production base will enhance production capacity for various forms of traditional Chinese medicine, including granules, tablets, capsules, and pills [3] Group 4: Integration and R&D Progress - The post-acquisition integration of Tianyuan Pharmaceutical is actively progressing, with collaborative efforts across production, marketing, procurement, and finance [3] - The company has 34 projects under review or in development, an increase of 8 projects compared to the same period last year, indicating ongoing investment in R&D [4] Group 5: Regulatory Approvals and Market Impact - The approval of iodinated contrast agent raw materials by Haichang Pharmaceutical is expected to enhance market competitiveness and sales growth in the raw material sector [4]

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 9 月 6 日投资者关系活动记录表 编号：【2024】第 024 号 | --- | --- | --- | |-------------------------|--------------------------|----------------------------------------------------| | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称 及人员姓名 | 浙商证券：刘玮奇、谢艺菲 | | | 时 间 | 2024 年 9 月 6 日 | | | 地 点 | 电话会议 | | | 上市公司接 待人员姓名 | 证券事务代表：孙志芳 | | | | | | | | | | | | | | | | 渐出现回暖趋势。 | | | | | | | 投资者关系活动 | | 工作，并努力扩大碘克沙醇注射液的市场份额。 | | 主要内容 ...